An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C
An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C
The purpose of this study is to provide anti-hepatitis C virus drugs to patients who received placebo + peginterferon alfa-2a + ribavirin in prior Bristol-Myers Squibb (BMS) studies and determine whether addition of these drugs results in higher cure rates in patients who previously failed therapy. Approximately 100 genotype 1b patients who received placebo in BMS study NCT01428063 (AI447-028) will receive active drugs in this study.
Intervention Model:
Peginterferon alfa-2a
Ribavirin
Daclatasvir
Asunaprevir
Key Inclusion Criteria:
Key Exclusion Criteria:
Buenos Aires, Buenos Aires 1119, Argentina
Ciudad de Buenos Aires, Buenos Aires C1121ABE, Argentina
Ciudad de Buenos Aires, Buenos Aires C1181ACH, Argentina
Prov. Buenos Aires, Buenos Aires 1629, Argentina
Prov de Santa Fe, Santa Fe Province 2000, Argentina
Westmead Nsw, New South Wales 2145, Australia
Clayton Vic, Victoria 3168, Australia
Thesaloniki, 54639, Greece
Cisanello (pisa), 56124, Italy
Viale Del Policlinico, 155, 00161, Italy